Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Omid Hamid

22PUBLICATIONS

179CO-AUTHORS

Medical devicesCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsTumour immunologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (22)

Sort by Publication Date:

|Feb 16, 2026

LOAd703-induced tumor microenvironment gene engineering in combination with atezolizumab in metastatic malignant melanoma: a phase I/II trial.

O Hamid, V Ekström-Rydén, I Mehmi

|Jul 25, 2025

First-in-Human Phase I/II Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid Tumors.

Omid Hamid, Dana B Cardin, F Stephen Hodi

|Jul 09, 2025

First-in-human phase I open-label study of the LAG-3 antagonist antibody INCAGN02385 in patients with select advanced or metastatic solid tumors.

John D Powderly, Martin E Gutierrez, Ani S Balmanoukian

|Jul 09, 2025

First-in-human phase I open-label study of the anti-TIM-3 monoclonal antibody INCAGN02390 in patients with select advanced or metastatic solid tumors.

Martin E Gutierrez, Shou-Ching Tang, John D Powderly

|Jun 02, 2025

Long-Term Efficacy and Safety of Lifileucel Tumor-Infiltrating Lymphocyte Cell Therapy in Patients With Advanced Melanoma: A 5-Year Analysis of the C-144-01 Study.

Theresa Medina, Jason A Chesney, Harriet M Kluger

|Jan 09, 2025

Phase II Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1-Pretreated Metastatic Non-Small Cell Lung Cancer and Metastatic Cutaneous Melanoma.

Sylvia M Lee, Omid Hamid, Robert Jotte

Pageof 4

Frequent Collaborators

3 joint publications

Inderjit Mehmi

3 joint publications

Georgina V Long

3 joint publications

Jeffrey Chou

3 joint publications

James M G Larkin

3 joint publications

Sajeve S Thomas

3 joint publications

Pippa G Corrie

2 joint publications

John M Kirkwood

2 joint publications

Harriet M Kluger

2 joint publications

Amod A Sarnaik

2 joint publications

Eric D Whitman

Frequent Collaborators

3 joint publications

Inderjit Mehmi

3 joint publications

Georgina V Long

3 joint publications

Jeffrey Chou

3 joint publications

James M G Larkin

Top Related Videos

A 3D Organotypic Melanoma Spheroid Skin Model

A 3D Organotypic Melanoma Spheroid Skin Model

Published on : May 18, 2018

Utilizing <sup>18</sup>F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing <sup>18</sup>F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on : Jul 21, 2018

See more related videos

Top Related Videos

A 3D Organotypic Melanoma Spheroid Skin Model

A 3D Organotypic Melanoma Spheroid Skin Model

Published on : May 18, 2018

Utilizing <sup>18</sup>F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing <sup>18</sup>F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on : Jul 21, 2018

See more related videos